- Paszek, Matthew J;
- DuFort, Christopher C;
- Rossier, Olivier;
- Bainer, Russell;
- Mouw, Janna K;
- Godula, Kamil;
- Hudak, Jason E;
- Lakins, Jonathon N;
- Wijekoon, Amanda C;
- Cassereau, Luke;
- Rubashkin, Matthew G;
- Magbanua, Mark J;
- Thorn, Kurt S;
- Davidson, Michael W;
- Rugo, Hope S;
- Park, John W;
- Hammer, Daniel A;
- Giannone, Grégory;
- Bertozzi, Carolyn R;
- Weaver, Valerie M
Malignancy is associated with altered expression of glycans and glycoproteins that contribute to the cellular glycocalyx. We constructed a glycoprotein expression signature, which revealed that metastatic tumours upregulate expression of bulky glycoproteins. A computational model predicted that these glycoproteins would influence transmembrane receptor spatial organization and function. We tested this prediction by investigating whether bulky glycoproteins in the glycocalyx promote a tumour phenotype in human cells by increasing integrin adhesion and signalling. Our data revealed that a bulky glycocalyx facilitates integrin clustering by funnelling active integrins into adhesions and altering integrin state by applying tension to matrix-bound integrins, independent of actomyosin contractility. Expression of large tumour-associated glycoproteins in non-transformed mammary cells promoted focal adhesion assembly and facilitated integrin-dependent growth factor signalling to support cell growth and survival. Clinical studies revealed that large glycoproteins are abundantly expressed on circulating tumour cells from patients with advanced disease. Thus, a bulky glycocalyx is a feature of tumour cells that could foster metastasis by mechanically enhancing cell-surface receptor function.